Investigators also glimpse to evaluate linvoseltamab in relapsed/refractory numerous myeloma as part of the phase three LINKER-MM3 demo. Experimental: Dose expansion_sub-inhabitants 2_lower dose of niraparib MTDs and/or candidate RP2Ds for elimusertib utilised together with niraparib in a lower set dose. Readily available archival tumor tissue ≤ 12 months aged, otherwise https://judyx111kvf3.dgbloggers.com/profile